Q3 2024 EPS Estimates for Nuwellis, Inc. (NASDAQ:NUWE) Lifted by Roth Capital

Nuwellis, Inc. (NASDAQ:NUWE) – Research analysts at Roth Capital lifted their Q3 2024 earnings per share (EPS) estimates for Nuwellis in a research note issued on Wednesday, August 28th. Roth Capital analyst J. Aschoff now expects that the company will post earnings of ($0.88) per share for the quarter, up from their previous forecast of ($0.99). Roth Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Nuwellis’ current full-year earnings is ($9.91) per share. Roth Capital also issued estimates for Nuwellis’ Q4 2024 earnings at ($0.36) EPS, FY2024 earnings at ($9.91) EPS, FY2025 earnings at ($2.46) EPS and FY2026 earnings at ($1.42) EPS.

Separately, Roth Mkm reaffirmed a “buy” rating and set a $17.00 price target on shares of Nuwellis in a research report on Tuesday, August 13th.

Nuwellis Stock Down 8.5 %

NUWE opened at $1.30 on Monday. The firm has a market cap of $2.43 million, a price-to-earnings ratio of 0.00 and a beta of 0.43. Nuwellis has a 52 week low of $1.17 and a 52 week high of $92.75. The business’s 50 day moving average is $2.96 and its two-hundred day moving average is $8.74.

Nuwellis Company Profile

Nuwellis, Inc, a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics.